← Oncology Approval Tracker

FDA DECISION ·

Bosulif capsules

bosutinib · Pfizer

FDA approvalNew formulationChronic myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Lower-strength 50 mg and 100 mg capsules for labeled Philadelphia chromosome-positive CML uses, including chronic-phase disease in patients aged one year or older who are newly diagnosed or resistant or intolerant to earlier therapy.

LAMPGEN ANALYSIS

Why it matters

The added capsule strengths support dosing across a wider range of patients with CML.

What research teams should watch

Track formulation and capsule strength in the medication record, especially for pediatric dose adjustments.

PRIMARY RECORDS

Sources